<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626286</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12324 CohMSM</org_study_id>
    <nct_id>NCT02626286</nct_id>
  </id_info>
  <brief_title>Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa</brief_title>
  <acronym>CohMSM</acronym>
  <official_title>Prevention of HIV Infection in Men Who Have Sex With Men in Sub-Saharan Africa: Feasibility and Interest of a Quarterly Preventive Global Care (CohMSM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Expertise France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coalition Internationale Sida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCAD-SIDA MALI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espace Confiance, Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programme PAC-CI, Abidjan, Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association African Solidarité</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espoir Vie-Togo - ONG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the feasibility and interest of a HIV quarterly&#xD;
      preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help&#xD;
      reducing HIV incidence in this key population, their female partners, and the general&#xD;
      population. This interventional, open label, multicenter, multidisciplinary cohort study will&#xD;
      be conducted in Burkina Faso, Ivory Coast, Mali and Togo.&#xD;
&#xD;
      All participants will receive a HIV quarterly preventive global care including:&#xD;
&#xD;
      i) data collection on health status, symptoms of sexually transmitted infections (STI) and&#xD;
      sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv)&#xD;
      counselling adapted for MSM, and v) the provision of condoms and lubricants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the feasibility and interest of a HIV quarterly&#xD;
      preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help&#xD;
      reducing HIV incidence in this key population, their female partners, and the general&#xD;
      population.&#xD;
&#xD;
      Regarding HIV-negative MSM, the specific objectives are to assess:&#xD;
&#xD;
        1. the acceptability of the preventive global care including quarterly monitoring and HIV&#xD;
           screening as well as the associated medical, behavioral and social factors, and&#xD;
&#xD;
        2. changes in sexual behavior among MSM during the project as well as the associated&#xD;
           medical, behavioral and social factors.&#xD;
&#xD;
      Regarding HIV-positive MSM, the specific objectives are to assess:&#xD;
&#xD;
        1. the acceptability of the preventive global care including antiretroviral therapy&#xD;
           initiation whatever the CD4 T cell count and the clinical stage, as well as the&#xD;
           associated medical, behavioral and social factors,&#xD;
&#xD;
        2. adherence and response to antiretroviral therapy as well as the associated medical,&#xD;
           behavioral and social factors,&#xD;
&#xD;
        3. changes in sexual behavior among MSM during the project as well as the associated&#xD;
           medical, behavioral and social factors,&#xD;
&#xD;
        4. risk of HIV transmission as well as the associated medical, behavioral and social&#xD;
           factors, and&#xD;
&#xD;
        5. describe the virologic characteristics (subtypes / circulating recombinant forms,&#xD;
           co-infection with multiple variants and transmitted and acquired resistance profiles).&#xD;
&#xD;
      Regarding healthcare professionals, the specific objective is to evaluate the perception of&#xD;
      the preventive global care.&#xD;
&#xD;
      This interventional, open label, multicenter, multidisciplinary cohort study will be&#xD;
      conducted in Burkina Faso, Ivory Coast, Mali and Togo.&#xD;
&#xD;
      All participants will receive a HIV quarterly preventive global care including:&#xD;
&#xD;
      i) data collection on health status, symptoms of sexually transmitted infections (STI) and&#xD;
      sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv)&#xD;
      counselling adapted for MSM, and v) the provision of condoms and lubricants.&#xD;
&#xD;
      In addition, vaccination against hepatitis B virus and annual tests for syphilis will be&#xD;
      offered. HIV-negative MSM will also be offered an HIV screening test at each quarterly visit.&#xD;
      HIV-positive MSM will be offered immediate support of HIV infection including antiretroviral&#xD;
      therapy. A total of 700 MSM over 18 years (500 HIV-negative and 200 HIV-positive) reporting&#xD;
      at least one anal sex (passive or active) with another man within the last three months will&#xD;
      be recruited and followed for 24 to 36 months. MSM lost to follow-up, transferred, died or&#xD;
      having seroconverted for HIV during follow-up will be replaced in their respective group&#xD;
      (seronegative or seropositive) by other MSM. The study will last 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">January 5, 2021</completion_date>
  <primary_completion_date type="Actual">January 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of people followed after 3 years compared to the number of persons included (retention in the program)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of performed visits/scheduled visits</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of performed tests/scheduled tests</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of sexually transmitted infections</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of unprotected anal sex</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiretroviral therapy initiation probability in HIV-positive MSM</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiretroviral therapy maintenance probability in HIV-positive MSM</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of antiretroviral therapy observance in HIV-positive MSM</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV-positive MSM with viral load&gt;1000 copies/mL</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV-positive MSM with CD4≤reference (or CD4&lt;100/mm3)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV-positive MSM with new or recurrent AIDS-defining events (clinical stage 4)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV-positive MSM died under antiretroviral therapy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV-positive MSM with detectable viral load and inconsistent condom use with a partner seronegative or with unknown HIV status</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV subtypes / circulating recombinant forms</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of co-infections with several viral variants</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of transmitted and acquired resistance mutations</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of male sex partners</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">885</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV quarterly global care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV quarterly global care</intervention_name>
    <arm_group_label>HIV quarterly global care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man over 18 years&#xD;
&#xD;
          -  Reporting at least one anal sex (passive or active) with another man within the last&#xD;
             three months&#xD;
&#xD;
          -  Able to reach the local site of the study&#xD;
&#xD;
          -  Agreeing to participate in the study and signing the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of antiretroviral therapy (except for pre- or post-exposure prophylaxis)&#xD;
&#xD;
          -  Participation in another biomedical or behavioral research on HIV or sexually&#xD;
             transmitted infections&#xD;
&#xD;
          -  Impairment of the person making his participation in the study, or information&#xD;
             understanding, difficult or impossible&#xD;
&#xD;
          -  Predictable protocol violation (geographical distance or other reasons)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Oasis, Association African Solidarité (AAS)</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Confiance, Espace Confiance</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Halles, ARCAD-SIDA</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoir vie Togo</name>
      <address>
        <city>Lome</city>
        <country>Togo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Mali</country>
    <country>Togo</country>
  </location_countries>
  <removed_countries>
    <country>Burundi</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Men who have sex with men</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

